CHMP says yes to Pfizer's Xalkori in NSCLC
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted conditional marketing approval for Pfizer's anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib 200mg and 500mg hard capsules).